Diagnostics News and Research

RSS

Everist Genomics' CardioDefender Device to be featured at Wearable Technologies Conference

Everist Genomics announced today that Executive Vice Chairman Alex Charlton will speak about its breakthrough CardioDefender Device at the Wearable Technologies Conference, January 30, 2012, in Munich.

30 Jan 2012

DNA sequencing for difficult diagnoses of mitochondrial diseases may hit clinics soon

Identifying complete DNA sequences could identify difficult-to-diagnose diseases in humans. This concept is being used for the first time in a clinic. MitoExome sequencing uses new technologies known as next-generation sequencing (NGS) to decode all of the genes associated with mitochondria. Mitochondria are a capsule shaped organelle present within the cell. It is the powerhouse of the cell and its genes are inherited completely from the mother.

29 Jan 2012

UH vision scientist hopes techniques lead to earlier diagnoses in glaucoma

A University of Houston (UH) vision scientist has received a $1.85 million grant from the National Institutes of Health (NIH) to investigate whether his techniques are more effective than others in understanding the earliest changes of glaucoma, which could lead to developing a way to earlier diagnose this potentially blinding disease.

27 Jan 2012

IDEXX fourth quarter revenues increase 8% to $307.2 million

IDEXX Laboratories, Inc., today reported that revenues for the fourth quarter of 2011 increased 8% to $307.2 million, from $283.8 million for the fourth quarter of 2010. Organic revenue growth, as defined below, was 7%. Earnings per diluted share ("EPS") for the quarter ended December 31, 2011 increased 8% to $0.67, compared to $0.62 for the same period in the prior year.

27 Jan 2012

GenPath, BioReference Labs to introduce OnkoMatch solid tumor genotype test

BioReference Laboratories, Inc. and its GenPath Oncology business unit and through its exclusive commercialization agreement with the Massachusetts General Hospital (MGH) is introducing its groundbreaking solid tumor genotype test.

27 Jan 2012

Technoclone, Roche enter strategic alliance to co-develop coagulation assays

Roche announced today that it has entered into a strategic alliance with Technoclone, a reagent specialist in thrombosis and cardiovascular diagnostics based in Vienna, Austria, to co-develop a complete range of coagulation assays.

From Roche Sequencing and Life Science 27 Jan 2012

Meridian Bioscience first quarter net sales increase 8% to $40.3 million

Meridian Bioscience, Inc., Cincinnati, Ohio today: reported first quarter net sales of $40.3 million, an increase of 8% from the same period of the prior fiscal year.

25 Jan 2012

BioTime obtains license from Wistar Institute for technology related to SP100 gene

BioTime, Inc. today announced that it has obtained an exclusive license from The Wistar Institute in Philadelphia, PA for technology related to a gene designated as SP100.

25 Jan 2012

Urological cancer experts to examine latest treatment, research findings at 27th Annual EAU Congress

International urological cancer experts will examine the latest treatment and research findings at the 27th Annual EAU Congress in Paris, France on 24-28 February 2012.

25 Jan 2012

OraQuick HIV1/2 test as accurate as traditional blood test

A saliva test used to diagnose the human immunodeficiency virus (HIV), is comparable in accuracy to the traditional blood test, according to a new study led by the Research Institute of the McGill University Health Centre (RI-MUHC) and McGill University.

25 Jan 2012

Roche proposes to acquire Illumina for $44.50 per share

Roche announced today that it is proposing to acquire all outstanding shares of Illumina, Inc. for $44.50 per share in cash, or an aggregate of approximately $5.7 billion on a fully diluted basis.

From Roche Sequencing and Life Science 24 Jan 2012

Johnson & Johnson fourth quarter sales increase 3.9% to $16.3 billion

Johnson & Johnson today announced sales of $16.3 billion for the fourth quarter of 2011, an increase of 3.9% as compared to the fourth quarter of 2010. Operational sales increased 4.0% and the negative impact of currency was 0.1%.

24 Jan 2012

OPKO acquires two new prostate cancer biomarkers from Arctic Partners

OPKO Health, Inc. today announced the acquisition of an exclusive license from Arctic Partners Ab Oy for two biomarkers in the kallikrein family which, used together with prostate specific antigen (PSA), can reduce the need for prostate biopsies by over 50%.

24 Jan 2012

Lab21 acquires new real time PCR technology

Lab21 Limited, the global specialist in personalized medicine and clinical diagnostics, today announces the completion of a worldwide license from Cooperative Diagnostics to use its suite of patents and expertise for the development of its growing pipeline of molecular diagnostic kits. Financial details of the agreement were not disclosed.

23 Jan 2012

A*STAR, GE Global Research join forces in integrated advanced medical imaging technologies

GE Global Research, the central technology development arm for GE Healthcare and all of GE's businesses, has signed a Memorandum of Understanding (MOU) with Singapore's Agency of Science, Technology and Research (A*STAR). This agreement will focus on advancing current medical imaging technologies and diagnostics to enable more accurate, earlier and faster clinical diagnoses of cancer and other diseases. The partnership between A*STAR and GE Global Research brings together two world-class research institutions, integrating their deep domain expertise in biomedical, science, and engineering capabilities to support this effort.

22 Jan 2012

FDA allows marketing of Stratify JCV Antibody ELISA test for PML

Today, the U.S. Food and Drug Administration allowed marketing of the first test to help determine the risk for a rare brain infection called progressive multifocal leukoencephalopathy (PML) in people using the drug Tysabri (natalizumab) to treat multiple sclerosis (MS) or Crohn's disease.

21 Jan 2012

FDA approves product label change for Biogen Idec's TYSABRI to treat MS

Today Biogen Idec and Elan Corporation, plc announced that the U.S. Food and Drug Administration (FDA) has approved a product label change for TYSABRI that will help enable individual benefit risk assessment for patients with multiple sclerosis.

21 Jan 2012

Sequenom prices underwritten public offering of 13,000,000 shares of common stock

Sequenom, Inc. today announced the pricing of an underwritten public offering of 13,000,000 shares of its common stock, offered at a price to the public of $4.15 per share.

20 Jan 2012

Banner Alzheimer's Institute presents results from Navidea AZD4694 study at 6th Annual HAI

Navidea Biopharmaceuticals, Inc. today announced that the Banner Alzheimer's Institute, Phoenix, AZ, made two presentations of results from an AstraZeneca-sponsored study on the assessment of Navidea's late-stage radiopharmaceutical imaging candidate, AZD4694, at the 6th Annual Human Amyloid Imaging Meeting (HAI), in Miami, FL.

20 Jan 2012

Risks of modifying flu strains to become highly transmissible in humans outweigh benefits

In this Journal Sentinel Online opinion piece, Thomas Inglesby, chief executive officer and director of the Center for Biosecurity of UPMC in Baltimore; Anita Cicero, chief operating officer and deputy director of the center; and D.A. Henderson, a distinguished scholar at the center, comment on a recent announcement by scientists that they have genetically modified a strain of H5N1 bird flu that is "capable of spreading through the air between ferrets that were physically separated from each other," indicating "it would be readily transmissible by air between humans."

19 Jan 2012

Diagnostics News and Research

Everist Genomics' CardioDefender Device to be featured at Wearable Technologies Conference

DNA sequencing for difficult diagnoses of mitochondrial diseases may hit clinics soon

UH vision scientist hopes techniques lead to earlier diagnoses in glaucoma

IDEXX fourth quarter revenues increase 8% to $307.2 million

GenPath, BioReference Labs to introduce OnkoMatch solid tumor genotype test

Technoclone, Roche enter strategic alliance to co-develop coagulation assays

Meridian Bioscience first quarter net sales increase 8% to $40.3 million

BioTime obtains license from Wistar Institute for technology related to SP100 gene

Urological cancer experts to examine latest treatment, research findings at 27th Annual EAU Congress

OraQuick HIV1/2 test as accurate as traditional blood test

Roche proposes to acquire Illumina for $44.50 per share

Johnson & Johnson fourth quarter sales increase 3.9% to $16.3 billion

OPKO acquires two new prostate cancer biomarkers from Arctic Partners

Lab21 acquires new real time PCR technology

A*STAR, GE Global Research join forces in integrated advanced medical imaging technologies

FDA allows marketing of Stratify JCV Antibody ELISA test for PML

FDA approves product label change for Biogen Idec's TYSABRI to treat MS

Sequenom prices underwritten public offering of 13,000,000 shares of common stock

Banner Alzheimer's Institute presents results from Navidea AZD4694 study at 6th Annual HAI

Risks of modifying flu strains to become highly transmissible in humans outweigh benefits

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News